Efforts are underway to spread cheer and give back to their community this holiday season.

Patients can now receive a diagnosis of IBS or other disorders of gut-brain interaction and begin treatment sooner through use of this criteria designed only for clinical use.

A new level of accuracy and specificity in allergy testing is now available. Easy to use and affordable, AllerSmart IgE allows people to take charge of their healthcare and make the first move. The 9 "Big Foods" tested, such as peanut, account for 90% of true food allergy - 29 key environmentals such as grass, dust mite, trees, weeds, cat, dog and molds complete the screen. This should not be confused with sensitivity or intolerance testing.

Could Hold the Clue to Creating Better Treatments for Rheumatoid Arthritis

Expanding their mission-based diagnostics services

Investment to be utilized for scaling the company and commercialization of Qsant™, a urine test that monitors the health of transplanted kidneys

Funding Supports Continued Development of the SensiTox™ B. anthracis Toxin Test

The health tech company Digital Diagnostics AG from Mainz, Germany, has received approval for clinical trials from a German ethics committee and the Federal Institute for Drugs and Medical Devices (BfArM). This is a crucial regulatory step in the ongoing approval process for the Digid Cantisense™ SARS-CoV-2 test in Germany. The aim of the clinical trials is to demonstrate the reliability of the new technology in comparison with conventional PCR tests. The new test is particularly suitable for access control at airports or at large-scale event

Abbas Vafai, Ph.D. inventor of shingles vaccine, Shingrix™, develops ZosterGent™ VZV Identification Reagent, a more sensitive test in detecting the shingles virus.

Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to further advance its biomarker discovery platform.

Life Sciences Veteran Andrew Wilsack Joins Team

Company focused on portable coronavirus testing begins clinical trials with Medical City Dallas

Seasoned Industry Veteran to Take Company Through Next Phase of Operations

SUGENTECH's COVID-19 IgM&IgG 5-10 minutes rapid test kit is listed on the U.S. FDA's database and can be used in the U.S., as stated in Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019, and is planning to go further to seek EUA from U.S. FDA.

For development of the breakthrough MultiPath platform and culture-free, anti-microbial susceptibility tests

Commits to deliver platform to enable targeted treatment at the onset of infection

Two-day event highlights investment trends and opportunities in Life Sciences

New Senior VP of R&D and Regulatory Affairs will help guide product development and regulatory clearance.

New videos include 1-1 clinician interviews and detailed product tour

Additional funds to support the company's diagnostic platform initiatives

FDA clearance is part of Company's three-part strategy to change the business paradigm for the molecular diagnostic industry

InDevR receives 510(k) market clearance for the first influenza diagnostic assay capable of distinguishing between seasonal and non-seasonal influenza A subtypes.